HOXA9 can restrict the progression of breast tumors by regulating the expression of the tumor suppressor gene BRCA1 [26]; however, there have so far been no investigations regarding whether promoter DNA methylation of HOXA9 could be used for predicting response or resistance to neoadjuvant chemotherapy in breast cancer patients. Here, BRCA1 is linked to breast carcinoma.